Corbus Pharmaceuticals Holdings, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $8.00K.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $58.00K.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $1.72M, a 672449.02% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $178.00K, a 91.10% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $2.00M, a 1437.69% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $130.00K.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $944.80K, a 24.90% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $8.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $178.00K 10-K · filed 2026-03-09 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.00M 10-K · filed 2026-03-09 |
| 2024-09-30 | $58.00K 10-Q · filed 2025-11-12 | $2.00M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.72M 10-Q · filed 2025-08-05 | $1.94M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $226.00K 10-Q · filed 2025-05-06 | $226.25K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $130.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $255.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | |
| 2023-03-31 | $129.75K 10-Q · filed 2024-05-07 | |
| 2021-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $944.80K 10-K · filed 2023-03-07 |
| 2021-09-30 | $250.00K 10-Q · filed 2022-11-08 | $1.38M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $50.00K 10-Q · filed 2022-08-09 | $1.40M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $894.80K 10-Q · filed 2022-05-10 | $1.64M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $182.23K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $756.46K 10-K · filed 2022-03-08 |
| 2020-09-30 | $271.93K 10-Q · filed 2021-11-12 | $1.35M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $286.31K 10-Q · filed 2021-08-12 | $995.83K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $15.99K 10-Q · filed 2021-05-13 | $812.22K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $773.62K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $386.81K 10-K · filed 2021-03-15 |
| 2019-09-30 | -$80.10K 10-Q · filed 2020-11-09 | $236.61K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $102.71K 10-Q/A · filed 2020-08-31 | $351.09K derived: sum of 4 quarters · filed 2020-08-31 |
| 2019-03-31 | $204.00K 10-Q · filed 2020-05-11 | $394.99K derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $347.64K 10-K · filed 2020-03-16 |
| 2018-09-30 | $34.38K 10-Q · filed 2019-11-07 | $418.08K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $146.61K 10-Q · filed 2019-08-08 | $391.95K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $156.66K 10-Q · filed 2019-05-09 | $265.90K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $80.44K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $189.49K 10-K · filed 2019-03-12 |
| 2017-09-30 | $8.25K 10-Q · filed 2017-11-08 | $216.80K derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-06-30 | $20.55K 10-Q · filed 2017-08-09 | $388.00K derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-03-31 | $80.25K 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $107.75K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $467.19K 10-K · filed 2018-03-12 |
| 2016-09-30 | $179.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | |
| 2015-12-31 | $5.59K 10-K · filed 2018-03-12 | |
| 2014-12-31 | $4.45K 10-K · filed 2016-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |